中文

Illumina falls 19% even as it raises its full-year forecast

By · AI-assisted, human-reviewed and edited · · Updated · 16 sources · Fact-checked · 5 min read

Why is Illumina stock down today?

Illumina shares fell about 19% on Friday, after the drop began after hours on Thursday, despite an earnings beat and higher full-year forecasts. StockStory called revenue a miss, but Illumina's $37 million reduction for expected customer tariff credits complicates that comparison. The reporting so far does not establish what drove the selling.

What it means

What changed
Illumina raised its 2026 revenue and adjusted earnings per share forecasts after third-quarter results exceeded its guidance.
What hasn't changed
Illumina reported 4.8% revenue growth excluding tariff effects, currency changes and acquisitions; its full-year forecast on that basis stayed above 4%.
Next · With fourth-quarter results (date not announced)
Illumina's detailed 2027 guidance, which management plans to give then.
Move
▼ 18.6%
Price
$290.06 → $235.99
Value lost
~$8.2B
Up this year before
▲ 121%
Q3 revenue growth
+4.2%
2026 revenue guide
$4.64–4.66B

Prices: official close, Nasdaq (Yahoo Finance daily history), Oct 30, 2026 · Company data: 10-Q, Jun 28, 2026 · What these numbers mean

Nasdaq official closing prices on Oct 29 ($290.06) and Oct 30, 2026 ($235.99). Investing.com reported an after-hours price of $255.88 on Oct 29. Value lost is our estimate, using the 151.0 million shares Illumina reported outstanding on Jul 24, 2026.

Snapshot at the Oct 30, 2026 close

Enterprise value
$36.5B
Price/sales
7.9×
P/E
43.2×
Price/FCF
38.3×
Revenue growth
+5%
Net debt
$911M

Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 28, 2026, filed Jul 31, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 28, 2026. Price $235.99 (official close, Nasdaq (Yahoo Finance daily history)); 151.0 million shares (10-Q cover, Jul 24, 2026). n/m = not meaningful (e.g. negative earnings).

What happened

Illumina, the DNA-sequencing company, reported a quarter that beat on profit and raised its forecast, but the stock fell about 12% in after-hours trading and closed down about 19% on Friday.

  • Illumina released third-quarter results after the market closed on Thursday, Oct 29, with a call at 4:30 p.m. ET. Its quarter ended Sep 27.
  • The stock had closed at $290.06, up 0.4%. Investing.com reported an after-hours price of $255.88, down 11.8%.
  • On Friday it closed at $235.99, down 18.6% (Nasdaq), after a low of $231.18 (Yahoo Finance). We estimate the drop erased about $8.2 billion of its roughly $44 billion market value.
  • The broader market also fell on Friday: the S&P 500 closed down 1.8% and the Nasdaq Composite 2.9%, while the SPDR S&P Biotech ETF (XBI) fell 1.1% (Yahoo Finance).
  • During Thursday’s regular session, the S&P 500 fell 0.3% and the Nasdaq Composite fell 1.4%, AP reported. Illumina’s drop came after that session ended.
  • Before the report, the shares had risen about 121% this year, from $131.16 at the end of 2025.

The results

Company figures are from Illumina’s Oct 29 release; analyst estimates are those reported by StockStory.

Q3 2026 Compared with
Reported revenue $1.13 billion (+4.2%) About $1.15 billion expected
Revenue excluding tariff effects $1.17 billion
Adjusted earnings per share (EPS), excluding tariff refunds $1.44 About $1.36 expected
2026 revenue forecast $4.64–4.66 billion $4.60–4.64 billion before
2026 adjusted EPS forecast $5.40–5.45 $5.30–5.40 before
  • Chief Executive Jacob Thaysen said healthy clinical demand and strong placements of its NovaSeq X sequencers drove results above guidance. Illumina placed more than 80 NovaSeq X instruments in the quarter, its prepared remarks say.
  • Organic revenue growth, excluding tariff effects, currency changes and acquisitions, was 4.8%; excluding Greater China as well, it was 4.7%. StockStory said organic growth missed estimates. The full-year forecasts, above 4% worldwide and above 5% outside Greater China, did not change.
  • Outside Greater China, revenue from sequencing supplies used by research and applied customers fell 6%, excluding tariff effects. Outside Greater China, sequencing-instrument revenue fell 2%, excluding tariff refunds, currency changes and acquisitions, according to Illumina’s presentation.
  • For the fourth quarter, Illumina guided to revenue of $1.22–1.24 billion and adjusted EPS of $1.51–1.56, both excluding tariff effects. We found no published consensus to compare these with.

Why the market reacted this way

The shares fell after the results, but the coverage so far does not establish a single cause.

  • StockStory called revenue a miss using the reported $1.13 billion. StreetInsider compared revenue excluding tariff refunds, $1.17 billion, with the same roughly $1.15 billion consensus. The $37 million of tariff credits is more than the gap, and the estimates’ treatment of them is unclear, so the revenue-miss label needs caution.
  • The revenue-forecast midpoint rose by $30 million, about 0.6%, by our calculation from Illumina’s guidance, and the organic growth forecasts stayed the same.
  • The adjusted EPS of $1.44 excludes the tariff refunds, so the profit beat did not come from them.
  • The report came after a 121% gain in the stock this year.
  • Evercore ISI kept its Underperform rating but raised its price target to $200 from $168, citing results above expectations excluding tariff refunds while noting “continued uncertainty around the growth outlook,” Investing.com reported on Friday.
  • An Investing.com analysis of the results said the reaction suggests investors “remain concerned about the company’s growth trajectory and the sustainability of its platform transition.”

What the US listing of MGI could mean

A day before Illumina’s results, the US moved against its main Chinese rival. No source we found has tied that to Thursday’s drop or estimated what it means for Illumina’s sales.

  • On Oct 28, the Department of Homeland Security, which chairs the Forced Labor Enforcement Task Force, added MGI Tech, BGI Genomics and BGI Group to the Uyghur Forced Labor Prevention Act Entity List, citing genetic testing in Xinjiang (Federal Register notice, Oct 29). US Customs and Border Protection will presume their goods are made with forced labor and bar them from import unless that presumption is rebutted, Reuters reported. The notice names MGI Tech, not its US subsidiary Complete Genomics.
  • MGI rejected the allegations and said its US business is a limited part of its overall business (Reuters).
  • For Illumina, the US matters far more than China: the US and Canada made up 55% of its revenue in the first half of 2026, and Greater China about 5% (our calculation from its 10-Q).
  • China added Illumina to its list of “unreliable entities” on Feb 4, 2025, and barred it from exporting sequencers into China from Mar 4, 2025, its annual report says. China later lifted that ban, but Illumina remains on the list, Reuters reported.
  • Matt Marlowe, a former BGI employee who writes the BridgeCross Bio newsletter, wrote on Oct 29 that significant new Chinese restrictions on the sector are “relatively unlikely”, with a symbolic or more limited response more plausible.

Does this change Illumina’s future?

What did NOT change

  • Illumina said clinical customers remained a growth driver. Revenue from sequencing supplies used by those customers outside Greater China rose 14%, excluding tariff effects, and management still expects mid-teens growth for the year.
  • Sales to research and applied customers remained weak outside Greater China. Management kept its forecast for a mid-to-high single-digit decline this year, while reporting signs that research activity was stabilizing.
  • Illumina’s presentation showed Greater China revenue rising 13%, or 7% excluding currency changes and acquisitions. The region includes China, Taiwan and Hong Kong.

What DID change

  • The 2026 revenue and EPS forecasts moved up, by $30 million and about 8 cents at the midpoints.
  • Management said it plans to give detailed 2027 guidance with fourth-quarter results. Thaysen described growth above 5% in sequencing supplies as a starting point, without issuing formal guidance.

Our read

The release itself contained a raised forecast and a profit beat; the open question is whether investors were reacting to the reported revenue figure, the modest size of the raise, or the stock’s run this year. The shares closed Friday down 18.6%; further analyst commentary may help explain the reaction.

The other view

Chief Executive Jacob Thaysen said healthy demand from clinical customers and strong placements of NovaSeq X DNA sequencers drove results above guidance.

Source: Illumina Q3 2026 earnings call (Investing.com transcript), Oct 29, 2026

What to watch next

Next few days
Analysts' notes on the quarter and the fourth-quarter outlook.
With fourth-quarter results (date not announced)
Illumina's detailed 2027 guidance, which management plans to give then.

Quick questions

Did Illumina cut its forecast?

No. It raised its 2026 forecast for revenue to $4.64–4.66 billion, from $4.60–4.64 billion, and for adjusted earnings per share to $5.40–5.45, from $5.30–5.40, both excluding tariff refunds. Its organic growth forecasts were unchanged.

What are the tariff refunds?

Illumina expects refunds of US import tariffs imposed under the International Emergency Economic Powers Act (IEEPA). They gave a $79 million benefit to its third-quarter costs, and Illumina cut revenue by $37 million for the part it expects to pass on to customers as credits.

Did tariff refunds increase adjusted earnings?

Illumina's $1.44 adjusted earnings-per-share figure excludes tariff refunds. Including them, adjusted earnings were $1.62 per share, according to its release.

Updates

  • : Corrected Oct 31: cash and investments now exclude $88M of equity securities and non-marketable investments that Illumina reports within short-term investments; enterprise value and net debt updated. Prices and dates unchanged.

About Illumina: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.